Can magnesium deficiency affect metabolic, cardiovascular, endocrine, and cellular energy pathways?

Magnesium is a central intracellular cofactor, so deficiency can plausibly produce multisystem effects rather than a single, isolated syndrome. The evidence is strongest for ATP-dependent metabolism, ion handling, and glucose–insulin regulation, with direct physiologic evidence also supporting cardiovascular effects.

Clinical and physiologic evidence

• Controlled dietary depletion reduced red-blood-cell and skeletal-muscle magnesium and increased oxygen cost during standardized exercise, consistent with impaired energy efficiency.
• In a 3-week magnesium-free diet study, reduced red-cell magnesium coincided with increased platelet aggregability; intravenous or oral magnesium restored red-cell magnesium and reduced platelet reactivity.
• Prospective observational evidence links lower circulating magnesium to cardiovascular mortality, sudden cardiac death, heart failure, and atrial fibrillation. A meta-analysis estimated a 30% lower cardiovascular-risk estimate per 0.2-mmol/L higher circulating magnesium, but these associations do not establish that supplementation prevents events.
• Metabolic/endocrine consequences are most convincingly insulin-related: low magnesium is linked with impaired insulin secretion, insulin resistance, altered glucose transport, and metabolic syndrome. This should not be generalized to all endocrine systems.

Mechanistic basis

• ATP is chiefly used as MgATP²⁻: magnesium stabilizes ATP phosphate groups and permits phosphoryl-transfer reactions essential to ATP production and utilization.
• MgATP supports Na⁺/K⁺-ATPase cycling, while magnesium also modulates calcium-channel activity.
• In vascular smooth muscle, magnesium restrains L-type Ca²⁺ influx; endothelial effects include support of nitric oxide and prostacyclin pathways. Low magnesium can therefore favor higher intracellular calcium, vasoconstriction, and impaired vasodilation.
• Magnesium supports insulin-receptor autophosphorylation and downstream IRS-1/2–PI3K–Akt signaling, as well as beta-cell ATP-dependent mechanisms of insulin secretion.

Bottom line

• Magnesium deficiency can affect metabolic, cardiovascular, insulin-related endocrine, and cellular-energy pathways. The biochemical rationale is particularly strong for ATP handling and ion transport; the clinical magnitude of vascular and insulin-related effects varies with tissue, severity, and duration of deficiency.